BNP Paribas Asset Management
RIGL icon

BNP Paribas Asset Management’s Rigel Pharmaceuticals RIGL Stock Holding History

BNP Paribas Asset Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.37M Hold
35,029
– – ﹤0.01% 1170
2026
Q1 		$947K Hold
35,029
– – ﹤0.01% 1173
2025
Q4 		$1.5M Buy
+35,029
New +$1.32M ﹤0.01% 1110

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Soleus Capital Management
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BNP Paribas Asset Management's RIGL Position: Q2 2026 in Review

BNP Paribas Asset Management held its Rigel Pharmaceuticals (RIGL) position steady in Q2 2026 at 35,029 shares worth $1.37M. The position accounts for ﹤0.01% of the portfolio, ranked #1170.

BNP Paribas Asset Management first reported a position in RIGL in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.5M in Q4 2025. 155 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • BNP Paribas Asset Management held 35,029 shares of Rigel Pharmaceuticals worth $1.37M as of Q2 2026.
  • BNP Paribas Asset Management left its Rigel Pharmaceuticals share count unchanged in Q2 2026.
  • Rigel Pharmaceuticals made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #1170 holding.
  • BNP Paribas Asset Management first reported a position in Rigel Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • BNP Paribas Asset Management's Rigel Pharmaceuticals position peaked at $1.5M in Q4 2025.
  • 155 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.